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OBJECTIVE: Chronic heart failure (CHF) is a disease
with a poor prognosis leading to incapacitating symptoms
with recurrent hospital admissions. The MEtoprolol
CR/XL Randomized Intervention Trial in congestive
Heart Failure (MERIT-HF) was terminated early due to
the decrease in mortality in the patient group receiving
additional to standard treatment Metoprol CR/XL
(MET). The aim of the presented study is to show the eco-
nomic besides the clinical beneﬁt. METHODS: A cost
beneﬁt approach was used based on published data of
hospitalisation days from the multicentre randomized
double-blind placebo-controlled MERIT-HF and on the
additional drug costs as calculated based on the trial. The
calculation was done from the German payers’ perspec-
tive, only direct costs were taken into account. Data on
drug costs were derived from the Ifap-Index (2003), dis-
counts from retail pharmacists, whole salers manufac-
turers and patients’ co-payments were taken into
consideration. Daily bed charges for hospital stay were
taken from the database of German private health insur-
ers. Two scenarios were calculated. First it was assumed
that no patient stayed in an intensive care unit (ICU).
Second it was assumed each patient admitted to a hospi-
tal stayed at least one day in an ICU. RESULTS: In the
MET-group (1990 patients) a decrease of 2090 hospital-
isation days was seen compared to the placebo-group
(2001). The adjusted costs for the prevented hospital
stays were €499,555 (normal ward) or €558,109 (addi-
tional ICU). According to MERIT HF additional treat-
ment costs are €524,782 maximum. This result is highly
sensitive to the mean duration of treatment. If the “real-
istic” treatment duration is only 5% (26 days) below the
maximum of 521 days the costs will be €474,621 and
offset the hospitalisation costs. CONCLUSION: The 
presented data were calculated conservatively but prove
that the clinical beneﬁt is mirrored by the economic
results for the German health care system. Nevertheless,
further analysis on the detailed MERIT-HF data is
needed.
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OBJECTIVES: Estimate the cost-effectiveness ratio of
treating high vascular risk patients with simvastatin in
France. METHODS: Data were extracted from the pub-
lished results of the MRC/BHF Heart Protection Study
(HPS) performed in UK. HPS compared the occurrence
of total and CHD deaths, major vascular events (MVE),
and major coronary events (MCE) in more than 20,000
high vascular risk patients (patients with diabetes, prior
stroke or other cerebrovascular disease, peripheral 
arterial disease, or with CHD). Patients were randomly
assigned to simvastatin (40mg/day) or placebo and fol-
lowed at least for 5 years. The cost-effectiveness analysis
was performed using French unit costs. Direct costs
included the extra costs of simvastatin and the beneﬁt
associated with avoided vascular events. Indirect costs
were not considered. Costs and beneﬁt were discounted
at 5%. RESULTS: All-cause mortality was reduced by
13% (RR = 0.87, p = 0.0003). There was a discounted
survival beneﬁt of 0.040 year per included patient. There
were highly signiﬁcant reductions of about one quarter in
the risk of ﬁrst event rate of MVE (RR = 0.76, p < 0.0001)
and of MCE (RR = 0.73, p = 0.0001). The absolute reduc-
tion of events during the 5-year period in the simvastatin
group was 5.4% for any major vascular event, 2.1% for
non fatal MI, 1.3% for non fatal stroke, 2.4 % for revas-
cularisation, 1.2% for fatal MI and 0.2% for fatal stroke.
The discounted extra cost of simvastatin was estimated
at €1994 ($1 = €1) taking into account the statins in the
placebo group. This cost was reduced to €1031 by con-
sidering the direct cost associated with avoided vascular
events. Cost-effectiveness ratio was then estimated at
€25,517 per life year gained (€22,000 to €50,000 in the
different patients subcategories, ratios well accepted as
being cost-effective). CONCLUSION: Treatment with
simvastatin in different subcategories of high vascular risk
patients is cost-effective in the French setting.
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OBJECTIVES: To evaluate the cost effectiveness of the
low-molecular-weight heparin enoxaparin 40mg once
daily (ENOX) relative to no pharmacological prophylaxis
(NPP) and to unfractionated heparin 5000 IU thrice 
daily (UFH) in the prevention of venous thromboembolic
